New kind of the scams: AXON. I posted at the IPO that it was doomed. They raised 2 Billion dollars on their IPO, their sole product being a failed Alzheimer's drug that they bought for 5 million bucks after it failed its Phase 2 trial.

Now, today, they announce that it failed again.

Down 17 points.

New market cap: 714 million.

So, for a company whose asset is a failed drug -- THAT is valued at SEVEN TIMES IPIX.